Concepedia

Validation of the Prognostic Utility of ESTRO/EORTC Oligometastatic Disease Classification: A Secondary Analysis From the Population-Based Phase II SABR-5 Trial

Sarah Baker, Benjamin Mou, W. Jiang, M Liu, Alanah Bergman, Devin Schellenberg, Abraham Alexander, Hannah Carolan, Siavash Atrchian, Tanya Berrang,

International Journal of Radiation Oncology*Biology*Physics · 2022 · 22 citations · 7 references

DOI

Concepts

References

7

Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial

David A. Palma, Robert Olson, Stephen Harrow et al. · The Lancet · 2019 · 1.9K citations

, , +15

Evaluation of Definitive Stereotactic Body Radiotherapy and Outcomes in Adults With Extracranial Oligometastasis

Ian Poon, Darby Erler, Roi Dagan et al. · JAMA Network Open · 2020 · 75 citations · Full text

, , +13

Evaluation of the prognostic value of the ESTRO EORTC classification of oligometastatic disease in patients treated with stereotactic body radiotherapy: A retrospective single center study

Jonas Willmann, Eugenia Vlaskou Badra, Selma Adilovic et al. · Radiotherapy and Oncology · 2022 · 46 citations · Full text

, , +17

Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5

Robert Olson, Mitchell Liu, Alanah Bergman et al. · BMC Cancer · 2018 · 28 citations · Full text

, , +17

Outcomes of metastasis-directed therapy of bone oligometastatic prostate cancer

Paul Rogowski, Christian Trapp, Rieke von Bestenbostel et al. · Radiation Oncology · 2021 · 26 citations · Full text

, , +17